Elk River Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$323K Hold
2,060
0.05% 92
2026
Q1
$315K Hold
2,060
0.05% 87
2025
Q4
$284K Hold
2,060
0.05% 90
2025
Q3
$264K Hold
2,060
0.04% 91
2025
Q2
$249K Hold
2,060
0.04% 88
2025
Q1
$238K Hold
2,060
0.04% 89
2024
Q4
$200K Hold
2,060
0.04% 97
2024
Q3
$237K Hold
2,060
0.04% 90
2024
Q2
$219K Hold
2,060
0.04% 86
2024
Q1
$207K Hold
2,060
0.04% 93
2023
Q4
$208K Hold
2,060
0.04% 107
2023
Q3
$210K Hold
2,060
0.05% 100
2023
Q2
$208K Buy
+2,060
New +$206K 0.04% 107
2021
Q1
Sell
-2,184
Closed -$206K 126
2020
Q4
$206K Buy
+2,184
New +$191K 0.07% 114

Other funds holding NVS

Elk River Wealth Management's NVS Position: Q2 2026 in Review

Elk River Wealth Management held its Novartis (NVS) position steady in Q2 2026 at 2,060 shares worth $323K. The position accounts for 0.05% of the portfolio, ranked #92.

Elk River Wealth Management first reported a position in NVS in Q4 2020 and has held it in 14 quarters since. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Elk River Wealth Management held 2,060 shares of Novartis worth $323K as of Q2 2026.
  • Elk River Wealth Management left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.05% of Elk River Wealth Management's portfolio in Q2 2026, its #92 holding.
  • Elk River Wealth Management first reported a position in Novartis in Q4 2020 and has held it in 14 quarters since.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Elk River Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.